Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Regulus Therapeutics Inc (NASDAQ:RGLS)

3.46
Delayed Data
As of Jul 25
 +0.03 / +0.87%
Today’s Change
2.44
Today|||52-Week Range
10.60
-60.32%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$181.0M

Company Description

Regulus Therapeutics, Inc. engages in the discovery and development of drugs target microRNAs to treat a broad range of diseases. It is developing RG-101, which targets miR-122, a host factor for the hepatitis C virus infection. The company was founded in September 2007 and is headquartered in San Diego, CA.

Contact Information

Regulus Therapeutics, Inc.
3545 John Hopkins Court
San Diego California 92121-1121
P:(858) 202-6300
Investor Relations:

Employees

Shareholders

Individual stakeholders35.36%
Other institutional33.24%
Mutual fund holders26.91%

Top Executives

Paul C. GrintPresident, Chief Executive Officer & Director
Joseph P. HaganCOO, Principal Financial & Accounting Officer
Michael HuangVice President-Clinical Development
Daniel R. ChevallardVice President-Finance & Accounting
Allison WeyVP-Investor Relations & Corporate Communications